Neuro-Tech Inc is a private clinical stage biotech company based in Boston, MA, dedicated to developing transformative therapies for chronic eye diseases. Their core platform technology, Encapsulated Cell Therapy (ECT), enables continuous production of therapeutic proteins to the eye, with a particular focus on improving the quality of life for individuals with chronic retinal diseases such as Macular Telangiectasia (MacTel). MacTel is a bilateral retinal disease that gradually leads to the loss of central vision, and Neuro-Tech's ECT platform releases Ciliary Neurotrophic Factor (CNTF), a protein that has shown promise in protecting against the progressive loss of photoreceptors.
With no known pharmacological treatment options available for MacTel currently, Neuro-Tech's innovative approach offers hope for patients experiencing blurring, distorted vision, trouble reading, and loss of central vision. The company has made significant strides in their research and development, with positive Phase 3 topline results for their NT-501 implant in MacTel. Neuro-Tech's commitment to advancing the field of ophthalmology is evident through their team of experts, numerous publications, and participation in industry conferences.
Generated from the website